Lineage Cell Therapeutics (STU:BT3) Short-Term Capital Lease Obligation : €1.04 Mil (As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Lineage Cell Therapeutics Short-Term Capital Lease Obligation?

Lineage Cell Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Jun. 2024 was €1.04 Mil.

Lineage Cell Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Dec. 2023 (€0.81 Mil) to Mar. 2024 (€1.01 Mil) and increased from Mar. 2024 (€1.01 Mil) to Jun. 2024 (€1.04 Mil).

Lineage Cell Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2021 (€0.74 Mil) to Dec. 2022 (€0.90 Mil) but then declined from Dec. 2022 (€0.90 Mil) to Dec. 2023 (€0.81 Mil).

Lineage Cell Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Lineage Cell Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Short-Term Capital Lease Obligation Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.10

0.63

0.74

0.90

0.81

Lineage Cell Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.91	0.88	0.81	1.01	1.04

Lineage Cell Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Lineage Cell Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (STU:BT3) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

LCTX:USA LCTX:Israel BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Lineage Cell Therapeutics Headlines

No Headlines